Corcept Therapeutics Incorporated · Healthcare
Survives a correction-sized 3-point cut to analyst growth.
At a 30.0% margin the price requires 6.8% 3y revenue CAGR against 40.6% consensus, a cushion of +30.9pt versus a 0pt correction cut. Cushion clears the cut, so the price survives the correction on consensus estimates. Launch-stage premium multiple; de-rating risk, no revenue channel.
Breaks if: relacorilant approval/launch slips and the 40.6% CAGR consensus resets. We re-check this against analyst estimates every evening.
10 years, at a 30% margin (analysts' margin, cut for cash conversion)
+24.6%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
6 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 79% of reported profit arrived as operating cash, so the test cuts the analysts' 52% margin to 41%. That leaves a cushion of +37pt instead of +42pt, and the smaller of the two decides the group. Two or more red flags: this name cannot come out on top, however large its cushion.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 22, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the 33rd percentile of published models, rejecting the most bullish targets and leaning bearish against a consensus that expects the company's growth to accelerate far beyond its recent pace.
Whether Lifyorli's prescription volumes can accelerate fast enough to bridge the gap from 12.8% current growth to the 25.2% the price requires — a question that unit volume data can directly answer.
What the price refuses to pay for, and the full reconstruction, on the CORT quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names